Can Cui, Ph.D., J.D.

• A startup focused on the discovery and development of transformative therapies for the unmet medical needs of cancer patients: IP, licensing, and corporate matters.°
• A biopharmaceutical company dedicated to the development of innovative anti-cancer metastasis and antiviral drugs: IP and corporate matters.
• A company developing novel therapeutics based on gene editing, RNA editing, and delivery technology: IP and technology transactions.
• A biotech venture capital positioned to rapidly translate scientific discoveries into innovative new medicines: China licensing matters.°
• A company pioneering transformation of cancer treatment by enabling CAR-T cancer therapies to work more effectively: various licensing and collaboration matters.°
• A medical device company dedicated to ending obesity: China collaboration.°
• A clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class antibody therapies for the treatment of patients with solid tumors and hematologic malignancies: China IP matters.°
• A biotechnology company developing antibody drug conjugates: China licensing dispute resolution.°
• A privately owned medical device company based in Silicon Valley, California, USA: China licensing matters.°
• A clinical stage, programmable cell therapy company focused on solid tumor cell therapies to defeat cancer: licensing dispute resolution.°
• A world leader in executing complex cell edits: various licensing transactions.°
• A company developing drugs that specifically target the tumor blood vessels of most solid tumors: corporate restructuring and China licensing matters.°
• A global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide: various technology transactions.°
• The only biotech company in China with publicly declared focus to develop Treg immune therapy: patent, corporate, and technology transactions matters.
• A preclinical stage biotherapeutics company developing cost-effective, non-invasive, and easily accessible technologies to cure lung disease and repair damaged lung tissue: sponsored research agreements.°
• A company discovering life-changing medicines and cures for people with viral and liver diseases: various technology transactions.°
• A medical device company committed to improving the experience of both patients and surgeons through innovative technologies: patent matters.°
• A biomedical company working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, healthier lives: China collaboration.°
• An innovative drug research and development company that focuses on the field of cellular immunotherapy: various licensing matters.°
• A family-owned medical device company that works with physicians to develop devices that are less invasive for patients: China strategies.°
• A company developing and manufacturing proprietary interventional liquid nitrogen spray cryotherapy systems: financing from China.°
• A company developing energy devices for various aesthetic and dermatology treatments: China regulatory matters.°
• A developer of novel, coordinated immunotherapy solutions for patients: various licensing transactions.°
• A developer of custom diagnostic solutions with a focus on large-scale, global diagnostic needs including antibody, molecular, and antigen tests in traditional and non-traditional settings: China supply matters.°
• Eluminex Biosciences: various licensing and collaboration transactions, including:
  • global exclusive license agreement with FibroGen, Inc. on biosynthetic cornea and other recombinant human collagen products.°
  • acquisition of Zuretinol assets from Retinagenix Holdings.°
• A leader in OLED microdisplay technology for the next generation of computing and imaging devices: China distribution matters.°
• A discovery research company developing revolutionary treatments for patients with genetic disorders: general corporate, asset transfer, financing, and licensing, and services agreements.°
• A developer of EV charging software and hardware for forward-thinking companies around the world: development services agreement.°
• A consumer health and wellness products platform focused on better-for-you consumer health & personal care brands and products: China patent and regulatory matters.°
• A biotech company that drives drug discovery on with AI: IP matters.°
• A pioneering vaccine company dedicated to developing innovative solutions for global health challenges: general corporate matters.°
• A medical research company to improve reproductive health care: China supply matters.°
• A biotechnology company developing innovative gene therapies and cell therapies that are affordable and therapeutically effective: various patent and licensing matters.°
• A developer of a differentiated pipeline of innovative antibody therapeutics that will potentially transform how cancers are treated: general corporate, IP, tax, cybersecurity, licensing, and dispute resolution matters.°
• The first company in China to use induced-pluripotent stem cells and mesenchymal stem cell technology to develop a new generation of universal cell therapy products to treat clinically incurable diseases: licensing and collaboration matters.°
• A global biopharmaceutical company with a focus on oncology, autoimmune diseases, and ophthalmic diseases: licensing and collaboration matters.°
• A medical device company capturing, promoting, and advancing the category of abdominal wall and pelvic floor health, using a multifaceted, gender-specific approach: consulting agreement and various collaboration matters.°
• A biopharmaceutical company engaged in discovery and development of novel cell therapies and biologics for oncology and autoimmune diseases: contract dispute resolution.°
• A biomedical research technology company dedicated to the development and application of tumor immunotherapy technology: licensing and collaboration matters.°
• A cancer therapeutics biotechnology company, located at LabCentral in Cambridge, Massachusetts: China collaboration.°
• A developer of mobile phototherapy systems: general corporate, regulatory, and trademark matters.°
• A global mRNA CDMO company headquartered in United States: patent strategies.°
• A pharmaceutical company developing innovative products of low regulatory risks and high market potentials: financing and regulatory matters.°
• A leading eClinical provider: China human genetic resources regulatory advice.°
• A bio-pharma company spun out from Stanford University and focusing on developing new therapeutics based on innovative drug delivery technologies to address unmet medical needs of human and companion animals: IP and technology transactions.°
• A biotechnology company specializing in the development of advanced therapeutic antibodies, particularly focused on neurodegenerative diseases such as Alzheimer's disease: general corporate matters.°
• A next-generation biotech company specializing in computational drug design for innovative therapeutics: IP and licensing matters.°
• A company that has nearly $10 billion in public equities, primarily in the technology sector: China IP due diligence.°
• A pharmaceutical company using cutting-edge tools to make therapeutic progress against the most challenging of targets: sale of a subsidiary.°
• A strategy software provider: IP matters.°
• A private, Canada-based biotech company focused on neuroscience therapeutics: technology transactions.°
• A high-tech biopharmaceutical enterprise that is dedicated to advancing global innovation in the discovery of new peptide drugs: various collaborations.°
• A company developing non-degrading molecular glues to tackle difficult drug targets to improve patient outcomes: various collaborations.°
• A biotechnology company headquartered in China’s Eye Valley: various licensing and collaboration matters.°
• A health care company pioneering the field of integrated diagnostics: China contract dispute resolution and subsidiary China data transfer matters.°
• A leading Chinese company in gene therapies based on gene editing: IP, licensing, and financing matters.°
• A company specializing in international investment and financing, market access consulting, import-export trade, market promotion, sales, production outsourcing, and global procurement services in the biopharmaceutical and medical device industries: general corporate matters.°
• A company that pioneers innovative therapies for cancer, genetic diseases, and autoimmune diseases: IP and various licensing and collaboration matters.°
• A leading antibody discovery service provider with a pioneering platform that can accelerate the process and capture all available data: general corporate and IP matters.°
• A pioneer in discovering the mRNA-dependent DNA repair pathway and developing next-gen treatment for cancer treatment: general corporate, financing, and collaboration matters.°
• A provider of a single integrated cloud-based management console: China IP dispute resolution matters.°
• A China-based, global-oriented R&D company focusing on innovative drugs for diseases in the field of nervous system and autoimmunity: various licensing and collaboration matters.°
• A high-tech biotechnology company co-founded by overseas experts, returnee scientists and local Chinese pharmaceutical entrepreneurs: various licensing, collaboration and financing matters, including collaboration with and investment by a global, science-led, patient-focused pharmaceutical company.°
• A privately held, clinical-stage biopharmaceutical company dedicated to the development of an in situ platform therapy optimized for metastatic solid tumor cancers that aims to achieve high response rates with potentially improved survival: general corporate, IP, and licensing matters.°
• A biologically-targeted radiation therapy company focused on developing novel treatment to improve the lives of patients with difficult-to-treat cancers: various distribution, license, and collaboration transactions, including with South Korean and Japanese collaborators.°
• A rapidly developing company primarily engaged in the production of heat sinks, fans, and related products: IP matters.°
• A company engaged in research, development, therapeutic trials, creation, production, operation, marketing, distribution of therapeutic products for the treatment of cancer: general corporate and collaboration matters.°
• A company developing a technology that combines the noninvasive diffuse reflectance spectroscopy with patented algorithms for detecting various skin properties and body health condition: various licensing transactions.°
• A company active in the field of research, development, therapeutic trials, creation, production, operation, marketing, distribution of therapeutic products for the treatment of cancer: general corporate and licensing matters.°
• A company developing multiple new medical technologies to treat various metabolic diseases, such as obesity, type 2 diabetes, and nonalcoholic fatty liver: collaboration matters.°
• Vazyme Biotech Co., Ltd: IP transactions and product distribution matters.°
• A company focused on R&D of innovative mRNA drugs and adjuvants: patent, technology transactions, and global trade matters.°
• A company building computer aided diagnosis algorithms and systems in clinical imaging to improve diagnostic accuracy and effectiveness: various distribution and collaboration matters.°
• A technology innovator with an integrated platform that accelerates biopharmaceutical research: collaboration matters.°
• A provider of new drug candidates through structure-based de novo drug design to accelerate drug discovery: various licensing and collaboration matters.°
• A Chinese national high-tech enterprise specializing in the research and industrialization of innovative drugs: various IP and technology transactions matters.°

°The above representations were handled by Dr. Cui prior to his joining Greenberg Traurig, LLP.

• Adjunct Faculty Member, The Chinese University of Hong Kong Faculty of Law, 2013-2016.
• Guest Lecturer, Santa Clara University School of Law, 2022-present.

• Listed, The Best Lawyers in America, "Ones to Watch," Technology Law, 2024
• Listed, The Legal 500 United States, Life Sciences, 2022-2023

• Member, The BayHelix Group, 2021-present
• Lifetime Member, Chinese Bioscience Association, 2021-present
• Lifetime Member, Sino-American Pharmaceutical Professionals Association, 2023-present